Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Borak, J; Diller, WF
   Phosgene exposure: Mechanisms of injury and treatment strategies
   JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
   
   J. Borak e W.F. Diller, "Phosgene exposure: Mechanisms of injury and treatment strategies", J OCCUP ENV, 43(2), 2001, pp. 110-119
2. Rotivel, Y; Goudal, M; de Fanti, AS
   Human rabies prophylaxis in France.
   MEDECINE ET MALADIES INFECTIEUSES
   
   Y. Rotivel et al., "Human rabies prophylaxis in France.", MED MAL INF, 31, 2001, pp. 193S-201S
3. Hanlon, CA; DeMattos, CA; DeMattos, CC; Niezgoda, M; Hooper, DC; Koprowski, H; Notkins, A; Rupprecht, CE
   Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis
   VACCINE
   
   C.A. Hanlon et al., "Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis", VACCINE, 19(28-29), 2001, pp. 3834-3842
4. Hanlon, CA; Niezgoda, M; Morrill, PA; Rupprecht, CE
   The incurable wound revisited: progress in human rabies prevention?
   VACCINE
   
   C.A. Hanlon et al., "The incurable wound revisited: progress in human rabies prevention?", VACCINE, 19(17-19), 2001, pp. 2273-2279
5. Sciuto, AM
   Posttreatment with ETYA protects against phosgene-induced lung injury by amplifying the glutathione to lipid peroxidation ratio
   INHALATION TOXICOLOGY
   
   A.M. Sciuto, "Posttreatment with ETYA protects against phosgene-induced lung injury by amplifying the glutathione to lipid peroxidation ratio", INHAL TOXIC, 12(4), 2000, pp. 347-356
6. Champion, JM; Kean, RB; Rupprecht, CE; Notkins, AL; Koprowski, H; Dietzschold, B; Hooper, DC
   The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure
   JOURNAL OF IMMUNOLOGICAL METHODS
   
   J.M. Champion et al., "The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure", J IMMUNOL M, 235(1-2), 2000, pp. 81-90
7. Quiambao, BP; Lang, J; Vital, S; Montalban, CG; Le Mener, V; Wood, SC; Miranda, E
   Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines
   ACTA TROPICA
   
   B.P. Quiambao et al., "Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines", ACT TROP, 75(1), 2000, pp. 39-52
8. Sabchareon, A; Lang, J; Attanath, P; Sirivichayakul, C; Pengsaa, K; Le Mener, V; Chantavanich, P; Prarinyanuphab, V; Pojjaroen-Anant, C; Nimnual, S; Wood, SC; Riffard, P
   A new vero cell rabies vaccine: Results of a comparative trial with human diploid cell rabies vaccine in children
   CLINICAL INFECTIOUS DISEASES
   
   A. Sabchareon et al., "A new vero cell rabies vaccine: Results of a comparative trial with human diploid cell rabies vaccine in children", CLIN INF D, 29(1), 1999, pp. 141-149
9. Sudre, P; Ruiz, DS; Fagard, C; Perrin, L; Hirschel, BJ
   HIV post-exposure prophylaxis (PEP): eligibility of sexually infected patients diagnosed at the time of primary infection
   SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
   
   P. Sudre et al., "HIV post-exposure prophylaxis (PEP): eligibility of sexually infected patients diagnosed at the time of primary infection", SCHW MED WO, 129(8), 1999, pp. 314
10. LANG J; GRAVENSTEIN S; BRIGGS D; MILLER A; FROESCHLE J; DUKES C; LEMENER V; LUTSCH C
    EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF A NEW, HEAT-TREATED HUMAN RABIES IMMUNE GLOBULIN USING A SHAM, POSTEXPOSURE PROPHYLAXIS OF RABIES
    Biologicals
    
    J. Lang et al., "EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF A NEW, HEAT-TREATED HUMAN RABIES IMMUNE GLOBULIN USING A SHAM, POSTEXPOSURE PROPHYLAXIS OF RABIES", Biologicals, 26(1), 1998, pp. 7-15
11. SABCHAREON A; CHANTAVANICH P; PASURALERTSAKUL S; POJJAROENANANT C; PRARINYANUPHARB V; ATTANATH P; SINGHASIVANON V; BUPPODOM W; LANG J
    PERSISTENCE OF ANTIBODIES IN CHILDREN AFTER INTRADERMAL OR INTRAMUSCULAR ADMINISTRATION OF PREEXPOSURE PRIMARY AND BOOSTER IMMUNIZATIONS WITH PURIFIED VERO CELL RABIES VACCINE
    The Pediatric infectious disease journal
    
    A. Sabchareon et al., "PERSISTENCE OF ANTIBODIES IN CHILDREN AFTER INTRADERMAL OR INTRAMUSCULAR ADMINISTRATION OF PREEXPOSURE PRIMARY AND BOOSTER IMMUNIZATIONS WITH PURIFIED VERO CELL RABIES VACCINE", The Pediatric infectious disease journal, 17(11), 1998, pp. 1001-1007
12. Lang, J; Simanjuntak, GH; Soerjosembodo, S; Koesharyono, C
    Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia
    BULLETIN OF THE WORLD HEALTH ORGANIZATION
    
    J. Lang et al., "Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia", B WHO, 76(5), 1998, pp. 491-495
13. LANG J; ATTANATH P; QUIAMBAO B; SINGHASIVANON V; CHANTHAVANICH P; MONTALBAN C; LUTSCH C; PEPINCOVATTA S; LEMENER V; MIRANDA M; SABCHAREON A
    EVALUATION OF THE SAFETY, IMMUNOGENICITY, AND PHARMACOKINETIC PROFILEOF A NEW, HIGHLY PURIFIED, HEAT-TREATED EQUINE RABIES IMMUNOGLOBULIN,ADMINISTERED EITHER ALONE OR IN ASSOCIATION WITH A PURIFIED, VERO-CELL RABIES VACCINE
    Acta Tropica
    
    J. Lang et al., "EVALUATION OF THE SAFETY, IMMUNOGENICITY, AND PHARMACOKINETIC PROFILEOF A NEW, HIGHLY PURIFIED, HEAT-TREATED EQUINE RABIES IMMUNOGLOBULIN,ADMINISTERED EITHER ALONE OR IN ASSOCIATION WITH A PURIFIED, VERO-CELL RABIES VACCINE", Acta Tropica, 70(3), 1998, pp. 317-333
14. TSIANG H
    RABIES VACCINES - A REVIEW OF PROGRESS TOWARDS IMPROVED EFFICACY AND SAFETY
    Biodrugs
    
    H. Tsiang, "RABIES VACCINES - A REVIEW OF PROGRESS TOWARDS IMPROVED EFFICACY AND SAFETY", Biodrugs, 10(4), 1998, pp. 317-328
15. BOTTIGER D; JOHANSSON NG; SAMUELSSON B; ZHANG H; PUTKONEN P; VRANG L; OBERG B
    PREVENTION OF SIMIAN IMMUNODEFICIENCY VIRUS, SIVSM, OR HIV-2 INFECTION IN CYNOMOLGUS MONKEYS BY PREEXPOSURE AND POSTEXPOSURE ADMINISTRATIONOF BEA-005
    AIDS
    
    D. Bottiger et al., "PREVENTION OF SIMIAN IMMUNODEFICIENCY VIRUS, SIVSM, OR HIV-2 INFECTION IN CYNOMOLGUS MONKEYS BY PREEXPOSURE AND POSTEXPOSURE ADMINISTRATIONOF BEA-005", AIDS, 11(2), 1997, pp. 157-162
16. PEREZ O; PAOLAZZI CC
    PRODUCTION METHODS FOR RABIES VACCINE
    Journal of industrial microbiology & biotechnology
    
    O. Perez e C.C. Paolazzi, "PRODUCTION METHODS FOR RABIES VACCINE", Journal of industrial microbiology & biotechnology, 18(5), 1997, pp. 340-347
17. STRADY A; LANG J; ROTIVEL Y; JAUSSAUD R; FRITZELL C; TSIANG H
    RABIES IMMUNOPROPHYLAXIS - CURRENT RECOMM ENDATIONS
    La Presse medicale
    
    A. Strady et al., "RABIES IMMUNOPROPHYLAXIS - CURRENT RECOMM ENDATIONS", La Presse medicale, 25(22), 1996, pp. 1023-1027
18. KHAWPLOD P; WILDE H; CHOMCHEY P; BENJAVONGKULCHAI M; YENMUANG W; CHAIYABUTR N; SITPRIJA V
    WHAT IS AN ACCEPTABLE DELAY IN RABIES IMMUNE GLOBULIN ADMINISTRATION WHEN VACCINE ALONE HAD BEEN GIVEN PREVIOUSLY
    Vaccine
    
    P. Khawplod et al., "WHAT IS AN ACCEPTABLE DELAY IN RABIES IMMUNE GLOBULIN ADMINISTRATION WHEN VACCINE ALONE HAD BEEN GIVEN PREVIOUSLY", Vaccine, 14(5), 1996, pp. 389-391
19. ERTL HCJ; XIANG ZQ
    NOVEL VACCINE APPROACHES
    The Journal of immunology
    
    H.C.J. Ertl e Z.Q. Xiang, "NOVEL VACCINE APPROACHES", The Journal of immunology, 156(10), 1996, pp. 3579-3582
20. XIANG ZQ; KNOWLES BB; MCCARRICK JW; ERTL HCJ
    IMMUNE EFFECTOR MECHANISMS REQUIRED FOR PROTECTION TO RABIES VIRUS
    Virology
    
    Z.Q. Xiang et al., "IMMUNE EFFECTOR MECHANISMS REQUIRED FOR PROTECTION TO RABIES VIRUS", Virology, 214(2), 1995, pp. 398-404
21. DIETZSCHOLD B
    MONOCLONAL-ANTIBODIES IN RABIES THERAPY
    CLINICAL IMMUNOTHERAPEUTICS
    
    B. Dietzschold, "MONOCLONAL-ANTIBODIES IN RABIES THERAPY", CLINICAL IMMUNOTHERAPEUTICS, 1(4), 1994, pp. 245-249
22. HONG HA; ROOIJAKKERS EJM; KE NT; GROEN J; OSTERHAUS ADME
    METHODS FOR THE PURIFICATION OF EQUINE RABIES IMMUNOGLOBULIN - EFFECTS ON YIELD AND BIOLOGICAL-ACTIVITY
    Biologicals
    
    H.A. Hong et al., "METHODS FOR THE PURIFICATION OF EQUINE RABIES IMMUNOGLOBULIN - EFFECTS ON YIELD AND BIOLOGICAL-ACTIVITY", Biologicals, 22(1), 1994, pp. 1-6
23. FESCHAREK R; FRANKE V; SAMUEL MR
    DO ANESTHETICS AND SURGICAL STRESS INCREASE THE RISK OF POSTEXPOSURE RABIES TREATMENT FAILURE
    Vaccine
    
    R. Fescharek et al., "DO ANESTHETICS AND SURGICAL STRESS INCREASE THE RISK OF POSTEXPOSURE RABIES TREATMENT FAILURE", Vaccine, 12(1), 1994, pp. 12-13
24. MONTANOHIROSE JA; LAFAGE M; WEBER P; BADRANE H; TORDO N; LAFON M
    PROTECTIVE ACTIVITY OF A MURINE MONOCLONAL-ANTIBODY AGAINST EUROPEAN BAT LYSSAVIRUS-1 (EBL1) INFECTION IN MICE
    Vaccine
    
    J.A. Montanohirose et al., "PROTECTIVE ACTIVITY OF A MURINE MONOCLONAL-ANTIBODY AGAINST EUROPEAN BAT LYSSAVIRUS-1 (EBL1) INFECTION IN MICE", Vaccine, 11(12), 1993, pp. 1259-1266
25. FISHBEIN DB; ROBINSON LE
    RABIES
    The New England journal of medicine
    
    D.B. Fishbein e L.E. Robinson, "RABIES", The New England journal of medicine, 329(22), 1993, pp. 1632-1638